3rd Next-Generation Conjugates Summit

Driving Innovation in Discovery and Chemistry, Validating Clinical Proof-of Concept and Streamlining CMC of Conjugates with Novel Payloads and Formats
Traditional ADCs have seen significant success in recent years, but still face many challenges, from limited payload capacities to significant toxicities.

Given these limitations, drug developers are venturing beyond the conventional boundaries of conjugate drug design, by exploring novel payloads and targeting formats, with companies including VincerX Pharma, Dyne Therapeutics, and Orum Therapeutics currently awaiting clinical validation.

Time: 8:30 AM – 5:00 PM

Venue details: Hotel Commonwealth, 500 Commonwealth Avenue, Boston, Massachusetts, 02215, United States

Prices: USD 2599.00 – USD 5097.00

Speakers: Amy Han, Executive Director, R AND D Chemistry, Regeneron, Bin Wu, Principal Scientist, Amgen Inc., and more